DDInter1340 DDInter1395
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Paritaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients . Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as paritaprevir. As a newer generation and directly acting HCV antiviral, paritaprevir products have better Sustained Virological Response (SVR) rates, higher barriers to resistance, fewer side effects, and a reduced pill burden compared to older agents such as , , , , and . By combining multiple antiretroviral medications into fixed dose products, the viral lifecycle can be targeted at multiple stages while simultaneously reducing the risk of developing resistant viral strains . Within Canada and the United States, paritaprevir is currently available in three fixed dose products: Viekira Pak (FDA), Technivie (FDA and Health Canada), and Holkira Pak (Health Canada). More specifically, paritaprevir prevents viral replication by inhibiting the NS3/4A serine protease of Hepatitis C Virus (HCV) [FDA Label]. Following viral replication of HCV genetic material and translation into a single polypeptide, Nonstructural Protein 3 (NS3) and its activating cofactor Nonstructural Protein 4A (NS4A) are responsible for cleaving genetic material into the following structural and nonstructural proteins required for assembly into mature virus: NS3, NS4A, NS4B, NS5A, and NS5B . By inhibiting viral protease NS3/4A, paritaprevir therefore prevents viral replication and function. In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Paritaprevir as a first line therapy option when used in combination with other antivirals for genotypes 1a, 1b, and 4. Depending on the genotype, Paritaprevir is often used in combination with other antivirals such as , , , and , with the intent to cure, or achieve a sustained virologic response (SVR), after 12 weeks of daily therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality . Treatment with direct acting antivirals such as paritaprevir is associated with very minimal side effects, with the most common being headache and fatigue [FDA Label]. Lack of significant side effects and short duration of therapy is a considerable advantage over older interferon-based regimens, which were limited by infusion site reactions, reduced blood count, and neuropsychiatric effects . Paritaprevir first came on the market as a fixed-dose combination product with , , and as the FDA-approved product Viekira Pak. First approved in December 2014, Viekira Pak is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with for the treatment of HCV genotype 1a without cirrhosis or with compensated cirrhosis. Paritaprevir is also available as a fixed-dose combination product with and as the FDA- and Health Canada-approved product Technivie. First approved in July 2015, Technivie is indicated in combination with for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. In Canada, paritaprevir is also available as a fixed-dose combination product with , , and as the Health Canada-approved, commercially available product Holkira Pak. First approved in January 2015, Holkira Pak is indicated for the treatment of HCV genotype 1b with or without cirrhosis, and when combined with for the treatment of HCV genotype 1a with or without cirrhosis.
Omeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paritaprevir
Omeprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Lansoprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paritaprevir
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paritaprevir
Omeprazole {u} (Compound) treats {v} (Disease) Barrett's esophagus
Barrett's esophagus {u} (Disease) is treated by {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paritaprevir
Omeprazole {u} (Compound) binds {v} (Gene) ATP4A
ATP4A {u} (Gene) is bound by {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paritaprevir
Omeprazole {u} (Compound) upregulates {v} (Gene) TIPARP
TIPARP {u} (Gene) is upregulated by {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paritaprevir
Omeprazole {u} (Compound) palliates {v} (Disease) prostate cancer
prostate cancer {u} (Disease) is palliated by {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paritaprevir
Omeprazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Cytochrome P450 2C19 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paritaprevir
Omeprazole {u} (Compound) downregulates {v} (Gene) TRAPPC3
TRAPPC3 {u} (Gene) is downregulated by {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paritaprevir
Omeprazole {u} (Compound) causes {v} (Side Effect) Muscle spasms
Muscle spasms {u} (Side Effect) is caused by {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paritaprevir
Omeprazole (Compound) resembles Esomeprazole (Compound) and Es
Omeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole (Compound) resembles Esomeprazole (Compound) and Es
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole (Compound) resembles Esomeprazole (Compound) and Es
Omeprazole (Compound) treats Barrett's esophagus (Disease) and Barrett's esophagus (Disease) is treated by Esomeprazole (Compound) and Es
Omeprazole (Compound) binds ATP4A (Gene) and ATP4A (Gene) is bound by Esomeprazole (Compound) and Es
Omeprazole (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is upregulated by Esomeprazole (Compound) and Es
Omeprazole (Compound) palliates prostate cancer (Disease) and prostate cancer (Disease) is palliated by Esomeprazole (Compound) and Es
Omeprazole (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class) and Cytochrome P450 2C19 Inhibitors (Pharmacologic Class) includes Esomeprazole (Compound) and Es
Omeprazole (Compound) downregulates TRAPPC3 (Gene) and TRAPPC3 (Gene) is downregulated by Esomeprazole (Compound) and Es
Omeprazole (Compound) causes Muscle spasms (Side Effect) and Muscle spasms (Side Effect) is caused by Esomeprazole (Compound) and Es